World health
The pursuit of global health: the relevance of engagement fordeveloped countries
Christopher P Howson, Harvey V Fineberg, Barry R Bloom
The globalisation of the world economy and the consequent increase in commerce, travel, and communication havebrought benefits to virtually every country. But these changes also bring risks that cannot be addressed adequatelywithin traditional national borders. These risks include emerging infectious diseases, resulting in part from increasedprevalence of drug-resistant pathogens; exposure to dangerous substances, such as contaminated foodstuffs, and bannedand toxic substances; and violence, including chemical and bioterrorist attack. By investing in global health, industrliasedcountries will not only benefit populations in desperate and immediate need of assistance, but also themselves—throughprotecting their people, improving their economies, and advancing their international interests. This paper describes therationale for involvement of industrialised countries in global health, and suggests a means for its coordination.
In April, 1997, the Board on International Health of the
economic, social, behavioural, political, scientific, and
US National Academy of Sciences’ Institute of Medicine
technological factors, many of which are changing at an
published a report entitled, America’s Vital Interest in
unprecedented rate in both the industrialised and
Global Health (in which the term “global health” referred
developing worlds. Globalisation of the world economy
to health difficulties, issues, and concerns that transcend
and the resulting increase in commerce, travel, and
national boundaries; may be influenced by circumstances
communication have benefited almost every country. But
or experiences in other countries; and are best addressed
these changes also carry risks that cannot be contained or
through cooperative actions and solutions). The Board
addressed adequately within traditional national borders.
argued that through investment in global health, the USA
International trade and labour markets, deepening poverty,
will protect its own people, improve its economy, and
political instability, and environmental degradation have
advance its international interests. The purpose of this
increased the movement of people across national borders
paper is to extend this argument one step further—by
to 1 million per day.1 Consequently, the industrialised
proposing that all developed countries can benefit similarly
countries face new threats, including emerging infectious
through active and coherent engagement in global health.
diseases, reflecting, in part, the increasing prevalence of
(The terms “developed country” and “industrialised
country” have evolved over time to include 23 countries:
substances, such as contaminated foodstuffs, and banned
Australia, Austria, Belgium, Canada, Denmark, Finland,
and toxic substances; and violence, including chemical and
Luxembourg, the Netherlands, New Zealand, Norway,Portugal, Spain, Sweden, Switzerland, the UK, and the
Changes in demography, particularly increased life
USA; the newly industrialised Asian economies—Hong
expectancy, are dramatically altering patterns of disease
Kong, Korea, Singapore, Taiwan, and China—are still
epidemiology and disease burden in all countries of the
classified as developing economies.) We believe that with
world. As life expectancy increases in the world’s poorer
their combined human and financial resources, and their
nations, chronic diseases of adulthood, such as heart
experience in the biomedical and health sciences,
disease and depression, are imposing new demands on
industrialised countries can, and must, have a key role in
health-care systems. With ever-growing public demands for
providing solutions for the increasingly complex and
health—spending on health care worldwide in 1990, for
widespread health difficulties the world now faces. This
example, took up 8% of the world’s economic output2—
paper describes the rationale for the involvement of
the need to balance private-sector and public-sector
industrialised countries in global health, and suggests a
responsibilities in health, to assess and improve quality of
health care, to control costs, and to establish rational andhumane priorities for health-resource allocations are
difficulties with which every national government is
Human health worldwide is profoundly affected by
Board on International Health, Institute of Medicine, National
All developed countries have a vital and direct stake in the
Academy of Sciences, 2101 Constitution Avenue, NW Washington,
health of people around the world; this stake derives both
DC 20418 (C P Howson PhD); Harvard University, Massachusetts
from enduring traditions of humanitarian concern and
Hall, Boston, MA (H V Fineberg PhD); and Howard Hughes Medical
from compelling reasons of enlightened self-interest.
Institute, Albert Einstein College of Medicine, Department ofMicrobiology, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Considered involvement can serve to protect citizens,
improve indigenous economies, and advance national and
Correspondence to: Dr Christopher P Howson
regional interests on the world stage.
THE LANCET • Vol 351 • February 21, 1998
conditions. In 1900, for example, roughly 5% of the
Panel 1: Factors contributing to disease re-emergence andexamples of associated infections
world’s people lived in cities with populations exceeding100 000. Today, an estimated 45%—more than 2·5 billion
people—live in large urban centres. The UN expects this
proportion to rise to 61% of the world’s population by the
year 2025. As Linden argues, “the health of cities in the
developed world depends in some measure on developingnations’ efforts to control new diseases and drug-resistant
strains of old ones incubating in their slums. The
developed world ignores at its peril the problem of Third
Chemical and biological terrorism—the 1995 terrorist
release of toxic sarin gas in the Tokyo subway systemturned the civilian risk of chemical and biological terrorism
from a threat into reality. Authorities discovered that the
Aum Shinrikyo cult in Japan had stockpiles of biological
agents and bacterial-culture media. A new generation ofchemical and biological terrorists has emerged with theability to strike anywhere and with the necessary
Improvement of national and regional economies
For all populations to achieve better health is desirable initself. But healthier populations in the developing world alsoprovide more vibrant markets for the goods and services of
industrialised countries. Investment in health, such as
diphtheria, whoopingcough (pertussis), cholera
education, can help break cycles of poverty and politicalinstability worldwide, and thus contribute to national
Source: adapted from Committee on International Science, Engineering, andTechnology (CISET), 1995.
economic development and the growth of such markets.
The global market, however, retains untapped potential,
particularly for vaccines, drugs, and medical devices. In
1992, expenditure on pharmaceuticals was US$220 billion,
All countries have a responsibility to protect their
or $40 per person, whereas expenditure on vaccines was
citizens—residents, soldiers, and travellers. To do this,
about $2 billion, and that on medical devices and
countries must be aware of developing threats to health,
equipment roughly $71 billion.6 As the markets of many
both inside and outside national borders. Examples of
developing countries continue to expand rapidly—such as
the middle-class markets of Asia and Latin America—theirneeds and potential purchasing power are also increasing.
Emerging and resurgent infectious diseases—AIDS has
In most developing countries, however, the domestic
taught the world that the battle against infectious diseases
pharmaceuticals industry is small, and faces significant
is far from over. The 1919 pandemic of another infectious
constraints on its growth: such as lack of scientific and
disease, influenza, killed 20 million people worldwide—a
technical infrastructure, and low capacity for research and
greater death toll than that of World War I. Prominent
development; import restrictions on raw materials; lack of
factors associated with the resurgence of infectious diseases
quality control; price restrictions; and weak distribution
(panel 1 and table) include: (a) increasing mobility of theworld’s population—given the growing movement of
people, goods, and services around the globe, no site is too
remote, no person too removed, and no organism too
isolated to guarantee human safety from infectious
diseases; (b) inappropriate and indiscriminate use of
antimicrobials—this has occurred in both developing and
developed countries, and has promoted the selection of
drug-resistant organisms. For example, the case-fatality
rate of multidrug-resistant tuberculosis in immuno-
competent people can be as high as 30–40%. Perhaps the
greatest cause for concern is the 1995 report of the
emergence of vancomycin-resistant Staphylococcus aureus in
Japan—since staphylococcus infections are common after
surgical procedures, and few effective drugs are available
against organisms resistant to penicillin, methicillin, and
people as a result of war, civil disorder, and economic need
*Resistance to isoniazid, rifampicin, and/or other drugs. Source: Martin Cetron, Grace Emori, Patrick Kachur, Gloria Kelley, and Robert Tauxe,
has led to an increase in refugees from 38 million to 60
US Centers for Disease Control and Prevention, personal communication, 1996.
million during this decade, and to a growing migration to
Drug-resistant infectious agents and percentage of infections
urban areas, often resulting in overcrowded living
that are drug resistant, by country or area
THE LANCET • Vol 351 • February 21, 1998
systems.6,7 With the exception of China, no developing
importance of global surveillance systems that can alert the
country is self-sufficient in essential pharmaceuticals. One
international communities to outbreaks of infectious
consequence is that as many as 2·5 billion people are
diseases. The necessary information and communications
estimated to have little or no regular access to essential
technology are available, yet no formal infectious-disease
surveillance system exists on a global scale.
For the foreseeable future, therefore, the introduction of
If such a system were in place, even small-scale
new drugs and vaccines in developing countries will
outbreaks of infectious diseases could be quickly identified.
depend on the pharmaceutical and vaccine industries in
Such networks could also be adapted to serve as early-
industrialised nations. Moreover, the rising costs of
warning systems for chemical or bioterrist attack, or for
research and development will require these companies to
breakdowns in the safety of the global food supply.
pursue growth in emerging markets as aggressively as
Laboratory capabilities for the monitoring of emerging
drug resistance of conventional pathogens are crucial to the
constraints are deterring industrial countries from
assessments of threats and to the development of
developing products that could benefit the health of people
alternative control strategies. Critical technical assistance
in the developing world. These constraints—which
could then be efficiently mobilised in response. Global
include failure to respect and enforce intellectual-property
infectious-disease experts, for example, could be brought
rights, drug piracy, pricing restrictions, and lack of
to the site or could use modern communication networks
consistency in standards of regulation and enforcement—
to assist in diagnosis and to support local authorities in
must be overcome if markets in the industrialised nations
their prevention and control measures. Clinical specimens
are to expand effectively to compete and provide needed
could be sent to centralised reference laboratories for
disease identification and to strengthen early-responsemeasures. A surveillance system would help to identify
Advancement of national and regional interests
outbreaks of previously unrecognised syndromes or
Governments are no longer the sole agents in the global-
diseases, making possible scientific approaches for rapid
health arena. Beyond national programmes, the global-
identification of the causative agent, for development of
health system now contains the private or commercial
diagnostic tools, and, eventually, for better means of
independent sector and non-governmental organisations,
The value of shared information for better health
such as universities, private foundations, and relief and
services—every country must face the difficulty of how to
advocacy organisations; the multilateral sector, including
provide improved health care at lower costs. Many are
multinationally funded organisations such as WHO, the
experimenting with new approaches. The international
comparative study of health-service delivery and financing
organisations, and the World Bank and regional
can offer lessons about how countries—industrialised and
development banks; and the bilateral sector, which involves
developing alike—might better achieve improved health
various government and overseas-development agencies
and more effective, affordable, and equitable health
that are funded by single governments or regional partners.
services for their populations. As life expectancy rises in all
This pluralism brings a strong need, and opportunity, for
countries, health difficulties become increasingly common
active national engagement in global-health issues. The
to all—particularly the burden of chronic, non-
commitment of the most developed countries to
communicable diseases, such as cardiovascular disease,
democratic principles, and their traditions of humanitarian
psychiatric illness, and neoplastic disease. National
and development assistance in foreign policy—from the
experiments with programmes addressing issues of
Marshall Plan to the current reconstruction activities in the
violence, injury, and substance abuse provide important
Balkans—form the historical basis for national leadership
opportunities to learn. Each country must gather and share
in this effort. What is less appreciated is the value and
information on the burden of disease; and international
power of the developed world’s scientific and economic
and national institutions must analyse the risks that
capabilities to provide a practical basis for coordinated
contribute to premature death and disability and assess
improvement of the health of all people—most critically,
cost-effective interventions to address the greatest health
perhaps, of the poorest people in the world. To fail to
burdens. For developed countries to actively participate in
anticipate, prevent, and relieve global health difficulties,
such efforts is clearly in their direct interests.
and to accept widening gaps in health between the
Value for money in acquisition of knowledge from
developed and developing worlds, diminishes national
international research and clinical trials—investment in
stature, compromises the credibility of the national
research and development abroad has benefited all
governments and international organisations, and neglects
countries profoundly. International collaboration in the
probably the most direct opportunity to address the
eradication of smallpox, for example, disposes of the global
fundamental issue of global equity—the health of people.
need to spend US$1 billion annually to vaccinate travellersand other citizens. Transmission of paralytic poliomyelitis
no longer occurs in the western hemisphere, and the global
campaign to eliminate polio and measles worldwide will
save millions of lives and vast resources. Many do not
Global surveillance and communication networks—the
appreciate that these successes required international trials
recent outbreaks of Ebola in Zaire, haemorrhagic Dengue
and research. Several diseases (malaria and cholera, for
fever in southern Mexico, drug-resistant tuberculosis in
example, and certain cancers and genetic diseases) can be
New York City, USA, and in large parts of the developing
world, bubonic plague in India, cholera in Peru, and
collaboration—either because the number of people
E coli O157:H7 in Japan and Scotland, underline the
affected is greater in certain overseas regions, or because
THE LANCET • Vol 351 • February 21, 1998
appropriate registries and databases are available only in
Panel 2: Landmark discoveries derived from internationalcooperation in biomedical sciences
others. In terms of efficient acquisition of scientificknowledge and value-for-money assessment of the
effectiveness of new medical interventions, international
scientific collaborations are essential (panel 2).
Improvement of national and regional economiesHealthy populations abroad represent growing markets for
businesses of the industrial world. If developed countries
invest in improving the health of other populations—
through the study and development of treatments for their
major illnesses, for example—their economic returns will
pharmaceutical and medical products need to be engaged;
currently, some 2·5 billion people worldwide have little or
no access to essential drugs.8 At the same time, with
pressures to contain health costs in industrialised nations,
increasing opportunities exist to expand industry into
emerging markets in developing countries. For example,
pharmaceutical drugs rose from US$17 in 1975 to $29 in
1990.6 With life expectancy increasing in almost all
countries, demand for health is growing worldwide. At the
pharmaceuticals to the developing world is concentrated in
a limited number of industrialised nations; ten countries—
eight from western Europe plus the USA and Japan—
produce roughly 90% of the new pharmaceuticals
vaccine soon to be licensed byWyeth/Lederle field tested in
introduced since 1960, with the European countries
responsible for 75% of all drugs exported to developingcountries.6 If people in developing nations are to have a
greater access to essential drugs, vaccines, and medical
devices, and if industrialised countries are to take
advantage of the expanding markets in these nations,national governments and international agencies must
undertake certain measures in response. Mechanisms to
increase incentives for industries to invest in research and
development on products that would primarily benefit
poor populations are needed most. Incentives could
development; safeguards on intellectual-property rights;
patents to increase development; and, when necessary, the
forging of partnerships between public and private sectors,
or the establishment of trust funds to ensure development
partly owing to internationalcollaborative studies
Advancement of national and regional interests
Each developed country has unique strengths to help
improve global health. Yet the potential of many, including
the USA, has not been fulfilled. We believe that with the
end of the Cold War, industrialised nations have much to
contribute in the battle against disease and the social and
economic inequities that exist in health. To improve thehealth of all populations should be a significant component
in the foreign policy of all industrialised countries, because
they possess the scientific and technological capability to
inhibitors—from extracts of plantscollected in Ghana, Malaysia, and
make such improvement possible. To assure future
leadership in health, we believe that the most developedcountries
investment in biomedical research on major global healthproblems; create incentives to make possible thedevelopment and provision of medical advances for thepoorest countries; forge expanded partnerships and cost-
*Alexis Shelokov, Salk Institute, USA, personal communication, 1996. Source: Philip Schambra and Robert Eiss, National Institutes of Health,
sharing with other governments and international donors;
and invest in the education and training of physicians,
THE LANCET • Vol 351 • February 21, 1998
researchers, and health-care workers from around the globe.
World Bank. World development report 1993: investing in health. New
The industrialised countries should also support collabora-
York: Oxford University Press, 1993.
tive international and regional action—for example, to
Committee on International Science, Engineering, and Technology. Global microbial threats in the 1990s: report of the NSTC Committee
strengthen WHO, the World Bank, and efforts by regional
on International Science, Engineering, and Technology (CISET)
development banks to promote health and sustained
working group on emerging and re-emerging infectious diseases.
development and to partner with industry in ways that
Washington DC: National Science and Technology Council.
could accelerate development of drugs and vaccines needed
Linden E. The exploding cities of the developing world. Foreign Affairs
in developing countries (drugs for malaria and HIV-1 and
AIDS, for example). By investing in global health,
Kaplan DE, Marshall A. The cult at the end of the world. New York:
developed nations will be able to improve the health of their
Ballance R, Pogany J, Forstner H. The world’s pharmaceutical
own populations, advance their respective economies, and
industries: an international perspective on innovation, competition and
promote humane values and moral leadership in a world of
policy. Prepared for UN Industrial Development Organization
opportunities and profound health needs.
Institute of Medicine. Pharmaceutical innovation and the needs of
developing countries. Washington DC: National Academy Press, 1979.
Garrett L. The return of infectious disease. Foreign Affairs 1996;
UN Development Program. Human development report. New York:
Public health
Public health at the crossroads: which way forward?
Public health represents society’s organised and publicly supported efforts to improve the health status of the entirepopulation; its focus is on the reduction of health inequalities by optimising the underlying determinants of health andpreventing disease. But public health is under threat and needs to be strengthened so that it is at the centre ofhuman endeavour—locally, nationally, and worldwide.
sanitation, food supplies, and urbanisation are also
Major improvements in the health of human populations
important determinants of health status that interact with
have occurred this century, with the pace of change
accelerating in developing countries since the 1950s.
More people live in poverty today than 20 years ago.
About a fifth of the world’s population, 1·3 billion people,
live on a daily income of less than US$1.5 Although most
behavioural factors that affect population health, have
of the world’s poor live in South and East Asia, sub-
contributed to these improvements. Declining death rates
Saharan Africa has the fastest growing proportion of people
are important, but relative inequalities in health status
who live in poverty. But poverty is not confined to
among and within countries are a major social concern.1
developing countries; in situations where absolute poverty
Improvements in life expectancy are not universal and, as
is rare, relative deprivation becomes more important.6
has been noted in several central and eastern European
More generally, in no society are women treated equally
countries, such gains have been reversed with the rapid
to men, and women, children, and older people are at
increase in death rates among middle-aged men.2 The
greatest risk of poverty. Global population growth is about
90 million per year, and about 90% of future growth will
unacceptable state of vital statistics worldwide, the
occur in the developing world. The health of people in less
importance of premature mortality in developing countries,
developed countries is at risk from environmental hazards,
most of which is preventable, and the growing burden of
such as unsafe food and water, as well as from hazards
non-communicable disease and injury.
associated with modern lifestyles, for example, air and
The main variations in health status among countries
result from environmental, socioeconomic, and cultural
Population growth interacts with two global threats to
factors, and medical care is of secondary importance.
public health: global environmental degradation and
Poverty is the most important cause of preventable death,
economic globalisation.8 The continued over-consumption
disease, and disability, although only a low level of income
of the world’s resources by wealthy countries is a major
per person is required to achieve acceptable life expectancy
contributor to environmental degradation. But it is
at the national level.4 Literacy, access to housing, safe water
unreasonable to expect the growing populations ofdeveloping countries to resist the pressures to consume,without drastic action to reduce the ecological demands of
Departments of Community Health (Prof R Beaglehole MD) and
Economic globalisation leads to uneven economic
Medicine (R Bonita MD), Faculty of Medicine and Health Science,University of Auckland, Private Bag 92 019, Auckland,
growth and increased economic inequality. Trade is the
driving force for globalisation which expresses itself in a
THE LANCET • Vol 351 • February 21, 1998
Bio Identical Hormone Replacement Therapy Bio-Identical hormone replacement therapy has been practiced in the United States since the 1980’s. However, dating back to the 11th century in China, doctors implemented this therapy. Writings discuss how in mediaeval times, doctors would collect the urine of young men and women, then precipitate the urine and make it into pil s and give it to emperors
Mechanisms of GABA receptor blockade by millimolarconcentrations of furosemide in isolated rat Purkinje cellsSergey N. Kolbaev ∗, Irina N. Sharonova, Vladimir S. Vorobjev, Vladimir G. Skrebitsky Brain Research Institute, Russian Academy of Medical Sciences, Moscow 103064, Russia Received 29 October 2001; received in revised form 27 February 2002; accepted 13 March 2002 Abstract The ac